ECSP034709A - Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 - Google Patents

Derivados de eteres utiles como agentes inhibidores de las isozimas pde4

Info

Publication number
ECSP034709A
ECSP034709A EC2003004709A ECSP034709A ECSP034709A EC SP034709 A ECSP034709 A EC SP034709A EC 2003004709 A EC2003004709 A EC 2003004709A EC SP034709 A ECSP034709 A EC SP034709A EC SP034709 A ECSP034709 A EC SP034709A
Authority
EC
Ecuador
Prior art keywords
alkyl
substituted
nr22a
nr16r17
nhs
Prior art date
Application number
EC2003004709A
Other languages
English (en)
Inventor
Thomas Victor Magee
Anthony Marfat
Robert James Chambers
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034709A publication Critical patent/ECSP034709A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

Compuestos útiles como inhibidores de las PDE en el tratamiento de enfermedades reguladas por la activación y desgranulación de eosonofilos, especialmente asma, bronquitis crónica y enfermedad pulmonar obstructiva crónica, de la fórmula (gráfico) en la que j es 0 ó 1, con la condición de que cuando j es 0, n debe ser 2; k es 0 ó 1; m es 1,2ó 3; n es 1 ó 2; W1 y W2 son -0-0; -S(=O),-. en que t es 0 , 1 ó 2, ó,N(R3)-; Y es =C(R1a)-ó-[N (O)k-en que k es 0 ó 1; R1a es -H, - F, -CI, -CN, -N=2, alquilo (C1 -C4), alquinilo (C2-C4). alquilo (C1-C3) Fluorado, alcoxi (C1-C3) fluorado, - OR16, ó -C(=o= NR22a R22b; R y RB son -H, -F. -CF3, alquilo (c1-C4), cicloalquilo (C3-C7), fenilo ó bencilo sustituido con 0-3 R10; ó RA y RB se toman juntos paraformar un resto espiro en que r y s son 0-4 con la condición de que r + s ha de ser >1 pero no > 5; XA es -CH2-, -CHF, -CF2, -NR15-. -0-, ó -S(=Oh-, en que t es 0,1; Rc y RD son los mismos que RA y RB excepto que uno de ellos debe ser -H; R1 yR2 son -H, -F, -CI, -CN, -N02, alquilo (C1-C4). alquilo (C1-C4), alquilo (C1-C3) fluorado, -OR16 ó -C(=0) NR22a R22b; R3 es -H, alquilo (C1-C4) fenilo, bencilo ó -OR16; R4, R5 y R6 son (a) -H, -F, -CI, alquilo (C2-C4) -R16, OR16. -S(=0)p R16, -S(0)R16, -OC(=0)OR16, -OC(=0)R16, -CN _NO2 -C (=0)NR16R17 -C (=0)NR16R17 -NR22 aC (=0)NR16R17 -NR22 aC(=NR12)NR16R17, - NR22aC(=NCN)NR16R17, -NR22aC(=N-N02)NR'6R'7 -C(=NR22a)NR16R'7, -CH2C(=NR22a) NR'6R'7, -OC(=NR22a)NR16R17, -OC(=N-N02)N R16R17, -NR16R17, CH2N R16R17, -NR22aC(=O)R16.-NR22aC(=O)OR16, -NR22aS(=O)R17, -S(=O)pN R16 R17; ó -CH2C(=NR22a)NR16 R17; en que p es 0,1ó 2; (b) alquilo (C1-C4) o alcoxi (C1-C4) sustituido con 0-3 de -F ó -CI; o 0 ó 1 de alcoxi (C1-C2)-carbonilo, alquil (C1-C2) -carbonilo ó alquil (C1-C2) -carboniloxi; ó (c) fenilo, bencilo. furanilo, tetrahidrofuranilo, oxetanilo, tienilo, tetrahidrotienilo, pirrolilo, pirrolidinilo, oxazolilo, oxazolidinilo, isoxazolilo, isoxazolidinilo, tiazolilo, tiazolidinilo, isotiazolilo, isotiaozolidinilo, isotiazolilo, isotiazolidinilo, pirazolilo, pirazolidinilo, oxadiazolilo, tiadiazolilo, imidazolilo, imidazolidinilo, piridinilo, pirazinilo, pirimidinilo, ptridazinilo, piperidinilo, piperazinilo, triazolilo, trizinilo, tetrazolilo, piranilo, azetidinilo, morfoliniJo, paratiazinilo, indolilo, indolinilo, benzo [b] furanilo, 2,3 -dihidro-benzofuranilo, 2- h-cromenilo, cromanilo, benzotienilo, 1-H-indazolilo, bencimidazolilo, benzoxazolilo, benzoisoxazolilo, benzotiazolilo, benzotiazolilo, quinolinilo, isoquinolinilo, fta 1 azinilo, quinazolinilo, quinoxalinilo ó purinilo, todos ellos sustituidos con 0-2 de R14, 0 (d) R5 y R6 se toman conjuntamente para formar un resto de fórmulas parciales (1.3.1) hasta (1.3.15), D es un grupo de fórmular parciales (1.1.1.) hasta (1.1.9.): (gráfico) en que es 1-3, con la condición de que cuando q es 2 ó 3, R9 ha de ser -H; v es 0-1; W3 es -0-, -N(R9)- ó -OC(=O)-; R7 es (a) -H; (b) alquilo (C1-C6), alquenilo (C2-C6) ó alquinilo (C2-C6), Todos ellos sustituidos con 0-3 de R10; (c) -(CH2)u-cicloalquilo (C3-C7) en que u es 0-2, sustituido con 0-3 de R10; o (d) fenilo o bencilo sustituido con 0-3 de R10; R8 es (a) tetrazol-5-ilo, 1,2,4-triazol-3-ilo, 1,2,3-triazol-3-on-5-ilo, 1,2,3-triazol-5-ilo, imidazol-2-ilo, imidazol-4-ilo, imidazol-4-ilo, imidazolidin-2-2on-4ilo, 1,2,4-oxadiazol-3-ilo, 1,2,4- oxadiazol- 5-on-3-ilo, 1,2,4-ozadiazol-3-on-5-ilo, 1,3,4-oxadiazolilo, 1,3,4-oxadiazol-2-on-5-ilo, oxazolilo, isoxazolilo, pirrolilo, pirazolilo, succinimidilo, glutarimidilo, pirrolidonilo, 2-piridonilo, 4-piridonilo, piridazin-3-onilo, tiadiazolilo, paratiazinilo; (b) indolilo, indolinilo, isoindolinilo, benzo [b] furanilo, 2,3-dihidro-benzofuranilo, 2-H-cromenilo, cromanilo, benzotienilo, 1 H-indazolilo,bencimidazolilo, benzoxazolilo, benzoisoxazolilo, benzotiazolilo, benzotriazolilo, benzotriazinilo, quinazolinilo, quinoxalinilo, pirazolo [3,4-d] pirimidinilo, pirimido [4,5-d]pirimidinilo, imidazo [1,2-a] piridinilo, pirido-piridinilo, pteridinilo ó purinilo, todos ellos opcionalmente sustituidos en un átomo de carbono con R14, en un átomo de nitrógeno con R15 y todas sus formas tautómeras, ó en un átomo azufre con 0-2 átomos de oxígeno; R9 es -H, alquilo (C1-C4), cicloalquilo (C3-C7), fenilo, bencilo, - (C=O)OR16, -C(=O)R16, OR16, alquil (C1-C2)-OR16 ó alquil (C1-C2)-OR16 ó alquil (C1-C2)-C(=O)OR16;ó (c) -O-P(=O)(OHh (fosfórico), -PH(=O)OH (fosfinico), -P(=O)(OHh (fosfónico), [P(=O)(OH)-O-alquilo (C1-C4)] (alquilo-fosfono), -P(=O) (OH)-O-alquilo (C1-C4) (alquil-fosfinilo), -P(=O(OH)NH2 (fosforamido), -P (=O) (OH)NHR25 (fosforamido sustituido), -O-S(=O)2OH (sulfurico), -S(=O)2OH (sulfónico), -S(=O)2NHR26 ó -NHS(=O)2R26 (sulfonamido) en que R26 es -CH#, CF3, u otoluilo, y acil-sulfonamido seleccionado entre el grupo que consta de -C(=O)NHS(=O)2R25, -C(=O)NHS(=O)2NH2, -C(=O)NHS(=O)2-alquilo (C1-C4), -C(=O)NHS(=O)2NH-alquilo (C1-C4), -C(=O)NHS(=O)2N[alquilo (C1-C4)2 -S(=O)2NHC(=O)alquilo (1-C4). -S(=O)2NHC(=O)NH2, -S(=O)2 NHC(=O)NH-alquilo (C1-C4), -S(O)2NHC(=O)N[alquilo (C1-C4)]2, -S(=O)2 NHC(=O)R25, -S(=O)2 NHCN, -S(=O2)NHC{=S)NH2, -S(=OhNHC(=S)NH-alquilo (C1-C4), -S(=O)2 NHC(=S)N[alquilo(C1-C4)2, ó -S(O)2 NHS(=O)2R25, en que R25 es _H, -alquilo (C1-C4), fenilo ó -OR16; J1 y J2 son un resto que comprende un sistema anular de carbonos saturado ó insaturado que es monocíclico de 3 a 7 miembros, ó que es policiclico condesado ó discontinuo de 7 a 12 miembros; en que opcionalmente un átomo de carbono de dicho sistema anular de carbonos puede ser reeempazado por un heeroátomo seleccionado entre N, O y S; y cuando se selecciona N, opcionalmente un segundo átomo de carbono de este puede ser reemplazado por un heteroátomo seleccionado entre N, ó y S; 0 una sal farmacéuticamente aceptable de este.
EC2003004709A 2001-01-31 2003-07-31 Derivados de eteres utiles como agentes inhibidores de las isozimas pde4 ECSP034709A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26549201P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
ECSP034709A true ECSP034709A (es) 2003-09-24

Family

ID=23010671

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2003004710A ECSP034710A (es) 2001-01-31 2003-07-31 Derivados biarilicos nicotinamida de utilidad como inhibidores de isozimas pde4
EC2003004709A ECSP034709A (es) 2001-01-31 2003-07-31 Derivados de eteres utiles como agentes inhibidores de las isozimas pde4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2003004710A ECSP034710A (es) 2001-01-31 2003-07-31 Derivados biarilicos nicotinamida de utilidad como inhibidores de isozimas pde4

Country Status (25)

Country Link
US (2) US6649633B2 (es)
EP (1) EP1355884A1 (es)
JP (1) JP2004520386A (es)
KR (1) KR20030074761A (es)
CN (1) CN1518542A (es)
BG (1) BG108038A (es)
BR (1) BR0116852A (es)
CA (1) CA2436535A1 (es)
CR (1) CR7025A (es)
CZ (1) CZ20031895A3 (es)
EA (1) EA200300621A1 (es)
EC (2) ECSP034710A (es)
EE (1) EE200300360A (es)
HU (1) HUP0400637A2 (es)
IL (1) IL156413A0 (es)
IS (1) IS6846A (es)
MA (1) MA26983A1 (es)
MX (1) MXPA03006887A (es)
NO (1) NO20033397L (es)
NZ (1) NZ526453A (es)
OA (1) OA12540A (es)
PL (1) PL364135A1 (es)
SK (1) SK8792003A3 (es)
WO (1) WO2002060875A1 (es)
ZA (1) ZA200304894B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
KR20040007583A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
WO2002094321A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
US6951869B2 (en) * 2002-02-26 2005-10-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
EP1424101A3 (en) * 2002-11-29 2004-08-18 NOZAKI, Masako Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
JP2006522151A (ja) * 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
GB0309781D0 (en) * 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050154006A1 (en) * 2004-01-09 2005-07-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on a scopineester and nicotinamide derivatives
WO2006073413A1 (en) * 2004-02-20 2006-07-13 The Board Of Trustees Of The University Of Illinois Blood pressure reduction in salt-sensitive
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP4793692B2 (ja) 2004-04-26 2011-10-12 小野薬品工業株式会社 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
WO2006070370A2 (en) 2004-12-29 2006-07-06 Hadasit Medical Research Services & Development Limited Stem cells culture systems
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
CA2684460C (en) 2007-04-18 2017-01-03 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102549167B (zh) 2009-05-12 2017-04-26 皇家飞利浦电子股份有限公司 作为前列腺癌标志物的磷酸二酯酶4d7
BRPI1007704A2 (pt) 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
DK2473045T3 (en) 2009-09-01 2016-12-12 Catabasis Pharmaceuticals Inc Niacin-FATTY ACID CONJUGATES AND THEIR USES
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011044141A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid fibrate derivatives and their uses
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
PT3013796T (pt) * 2013-06-27 2020-03-26 Lg Chemical Ltd Derivados biarílicos como agonistas de gpr120
US9630935B2 (en) * 2013-09-17 2017-04-25 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
EP3328995B1 (en) 2015-07-29 2021-03-31 Hadasit Medical Research Services And Development Large scale production of retinal pigment epithelial cells
EP3331995A1 (en) 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
CN108138144A (zh) 2015-08-05 2018-06-08 细胞治疗神经科学有限公司 视网膜色素上皮细胞的制备
HUE070900T2 (hu) 2015-10-26 2025-07-28 Cell Cure Neurosciences Ltd Eljárás retinális pigmentepitélium-sejtek elõállítására
US9725406B1 (en) 2016-10-13 2017-08-08 Resolvex Pharmaceuticals Inc. Substituted hydroxystilbenes and their therapeutic applications
WO2018146679A2 (en) 2017-02-08 2018-08-16 Hadasit Medical Research Services And Development Ltd. Photoreceptor cells for the treatment of retinal diseases
US20200085882A1 (en) 2017-03-16 2020-03-19 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
BR112020013238A2 (pt) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
EP3787612A4 (en) * 2018-05-04 2021-11-17 Remedy Plan, Inc. CANCER TREATMENTS AGAINST CANCER STEM CELLS
JP7520820B2 (ja) 2018-09-20 2024-07-23 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 筋萎縮性側索硬化症の治療方法
PH12022551081A1 (en) 2019-11-06 2024-06-19 Remedy Plan Inc Cancer treatments targeting cancer stem cells
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN111888349B (zh) * 2020-07-29 2021-10-22 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 印楝素在制备促进缺血超长随意皮瓣存活药物的作用
JP2024522608A (ja) 2021-06-09 2024-06-21 リネージ セル セラピューティクス インコーポレイテッド 網膜の疾患および症状を処置するための方法および組成物
CA3225834A1 (en) 2021-07-28 2023-02-02 Lineage Cell Therapeutics, Inc. Expansion of retinal pigment epithelium cells
IL316305A (en) 2022-04-25 2024-12-01 Hadasit Med Res Service Methods and preparations for treating vision loss

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140772A5 (en) 1971-06-07 1973-01-19 Aries Robert Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) * 1979-10-01 1981-06-02 Stauffer Chemical Company N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) * 1986-01-13 1987-09-08 Stauffer Chemical Company N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
EP0500989B1 (en) 1991-02-27 1998-12-09 Lacer, S.A. N-(alpha-substituted-pyridinyl) carbonyl dipeptide antihypertensive agents
DE4200323A1 (de) 1992-01-09 1993-07-15 Bayer Ag Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
PT710109E (pt) 1993-06-18 2005-01-31 Smithkline Beecham Corp Metodo para identificar um inibidor de pde iv
JP3406689B2 (ja) 1994-03-15 2003-05-12 株式会社大塚製薬工場 ナフチリジン及びピリドピラジン誘導体
US5618027A (en) * 1994-07-20 1997-04-08 Nevrekar; Venkatesh R. Gate valve
JPH10511398A (ja) 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション ４，４−（二置換）シクロヘキサン−１−カルボキシレート単量体および関連する化合物
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US5922557A (en) 1997-01-09 1999-07-13 Merck & Co., Inc. System for stably expressing a high-affinity camp phosphodiesterase and use thereof
CA2285548C (en) 1997-04-04 2006-07-11 Pfizer Products Inc. Nicotinamide derivatives
GB9715584D0 (en) * 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
UA67753C2 (uk) 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AR015190A1 (es) 1997-10-23 2001-04-18 Smithkline Beecham Corp Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
HUP0204262A2 (hu) * 2000-01-31 2003-04-28 Pfizer Products Inc. Benzogyűrűvel kondenzált heterociklusos csoportot tartalmazó nikotinamid-származékok, továbbá e vegyületeket tartalmazó, a PDE4 izozimek szelektív gátlására adható gyógyászati készítmények
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4

Also Published As

Publication number Publication date
KR20030074761A (ko) 2003-09-19
IS6846A (is) 2003-06-16
ZA200304894B (en) 2004-06-24
EA200300621A1 (ru) 2003-12-25
HUP0400637A2 (hu) 2004-06-28
CR7025A (es) 2003-11-25
PL364135A1 (en) 2004-12-13
US6649633B2 (en) 2003-11-18
WO2002060875A8 (en) 2003-07-31
OA12540A (en) 2006-06-05
EE200300360A (et) 2003-12-15
IL156413A0 (en) 2004-01-04
ECSP034710A (es) 2003-09-24
CA2436535A1 (en) 2002-08-08
MA26983A1 (fr) 2004-12-20
MXPA03006887A (es) 2003-11-13
BG108038A (en) 2004-07-30
BR0116852A (pt) 2004-02-25
CN1518542A (zh) 2004-08-04
US20020193612A1 (en) 2002-12-19
NO20033397D0 (no) 2003-07-30
US6953810B2 (en) 2005-10-11
JP2004520386A (ja) 2004-07-08
SK8792003A3 (en) 2004-09-08
NZ526453A (en) 2005-01-28
US20040048903A1 (en) 2004-03-11
CZ20031895A3 (cs) 2004-08-18
NO20033397L (no) 2003-09-19
WO2002060875A1 (en) 2002-08-08
EP1355884A1 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
AR032522A1 (es) Derivados de eteres utiles como agentes inhibidores de las isozimas pde4
AU2021330865B2 (en) Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof
ES2612954T3 (es) Compuestos de quinoxalina
AU2017228870B2 (en) Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
ES2459195T3 (es) Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
AU2002221344B2 (en) Antiviral agents
ES2923290T3 (es) Inhibidores de PRC2
EP2414369B1 (en) Imidazo[2,1-b][1,3,4]thiadiazole derivatives
ES2717688T3 (es) Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
EP1581472A2 (en) Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
PT2888241T (pt) Derivados da 3,6-diidropirimidina substituídos 2,4,5,6-como inibidores da polimerase do vírus da hepatite b (vhb) para o tratamento, p. ex., da hepatite crónica
ES2839201T3 (es) Derivados de anillo (hetero)aromático sustituidos en carboxilo y método de preparación y usos de los mismos
TW201311B (es)
JP2024539068A (ja) Ｎｌｒｐ３阻害剤として有用な縮合二環式ヘテロアリール化合物
ES2357076T3 (es) Compuestos para el tratamiento de la hepatitis c.
RU2605745C2 (ru) Соединения алкилсульфинил-замещенных тиазолидов
ES2364530T3 (es) Nuevos derivados de amida del ácido 2-aril-tiazol-4-carboxílico, su preparación y uso como medicamento.
ES2387706T3 (es) Nuevos derivados de amidas de ácidos 2-hetaril-tiazol-4-carboxílicos, su preparación y su utilización como un medicamento
BR112020008762A2 (pt) indol-2-carboxamidas amino-tiazol substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv)
DE60203652D1 (de) Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyms
CA2953798A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
AR062224A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden.
AR076310A1 (es) 4-azetidinil-1-heteroaril ciclohexanos sustituidos antagonistas de ccr2,composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos en el tratamiento de diabetes,obesidad y otras enfermedades.
AU2007270082A1 (en) New pyridine analogues
BRPI0713401A2 (pt) composto, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação plaquetária